← Back to Clinical Trials
Recruiting NCT03094026

NCT03094026 Cognitive Training Intervention and Attitudes Towards Genetics

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03094026
Status Recruiting
Phase
Sponsor University of Alabama at Birmingham
Condition Cognitive Impairment
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2017-08-21
Primary Completion 2027-07

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
LumosityLumosity (waitlist control)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2017-08-21 with a primary completion date of 2027-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

A pilot study to evaluate feasibility of enrollment of patients in an intervention to improve neurocognitive function in hematopoietic cell transplantation (HCT) survivors using the cognitive training Lumosity program. In addition, patients' interest in receiving information regarding genetic risk of cognitive impairment post-HCT will be measured.

Eligibility Criteria

Inclusion Criteria: * ≥ 21 years old at time of allogeneic HCT performed at UAB * Outpatient and between 3 and 6 months post HCT * English speaking * Possess access to an internet-connected home computer Exclusion criteria: * History of pre-existing neurological disorder or documented major psychiatric disorder; significant auditory, visual, or motor impairments * Participated in neuropsychological intervention within the past 6 months * History of color blindness

Contact & Investigator

Central Contact

Noha M Sharafeldin, MD,MSc, PhD

✉ nsharaf@uab.edu

📞 2056382144

Principal Investigator

Noha M Sharafeldin

PRINCIPAL INVESTIGATOR

University of Alabama at Birmingham

Frequently Asked Questions

Who can join the NCT03094026 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, studying Cognitive Impairment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03094026 currently recruiting?

Yes, NCT03094026 is actively recruiting participants. Contact the research team at nsharaf@uab.edu for enrollment information.

Where is the NCT03094026 trial being conducted?

This trial is being conducted at Birmingham, United States.

Who is sponsoring the NCT03094026 clinical trial?

NCT03094026 is sponsored by University of Alabama at Birmingham. The principal investigator is Noha M Sharafeldin at University of Alabama at Birmingham. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology